Lamassu Pharma
Durham
About Lamassu Pharma
Lamassu Pharma is a biotech startup that solves the critical unmet medical need for severe acute pancreatitis. Their lead candidate is a novel small molecule therapy for acute pancreatitis. This was developed at Mayo Clinic by leading scientists and has profound preclinical efficacy to completely mitigate mortality and morbidity associated with severe acute pancreatitis. We are currently focused on the continued development of this compound through safety testing in preparation for definitive clinical trials. Our ultimate goal is to save the lives of patients afflicted with this disease.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $7.4M
- Funding stage: Early Stage Venture
- Last round: Grant (Jun 2025)
- Website: lamassubiotech.com
- Phone: 1-919-667-8571
Industries & Categories
Biotechnology, Health Care, Pharmaceutical, Therapeutics
Canonical: https://fsome.com/organization/lamassu-pharma-92504 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.